
Entecavir versus tenofovir
The cumulative probabilities of hepatocellular carcinoma
(HCC), death, or liver transplant were studied in 2,897 treatment-
naïve patients with hepatitis B who started treatment
with either entecavir (ETV) or tenofovir deoxyfumarate (TDF)
between 2012 and 2014.
EACS Guidelines
Magazine